Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052: Summary.

Slides:

Advertisements

Similar presentations

William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.

Advertisements

IPEC - Fundação Oswaldo Cruz Rio de Janeiro -Brazil Women and Trials in Low and Middle-income settings: the clinical investigators Perspective August 6,

The Cost-effectiveness of Treatment as Prevention: Analysis of the HPTN 052 Trial Supported by NIAID R01 AI and HPTN 052 Rochelle Walensky, MD, MPH.

Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052.

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.

Analysis of Genetic Linkage of HIV from Couples Enrolled in the HPTN 052 Trial Susan H. Eshleman, MD/PhD HPTN Network Laboratory Johns Hopkins Univ. School.

The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Linda-Gail Bekker The implementation of this project was made possible.

Leading By Example in the Public Health Approach to Antiretroviral Therapy Operations Research Agenda: Innovation & Collaboration What Can Industry Bring.

Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD Moderator: John Bartlett, MD Discussants: Cal Cohen, MD.

Washington D.C., USA, July 2012www.aids2012.org Acceptability of Pre-Exposure Prophylaxis among MSM and TG in Northern Thailand Daniel Yang, MD Candidate*

MIT Washington DC Program Internship Presentation.

My Internship Experience with the National Institute of Health Summer 2014 Sidik Abdul-Mumuni USF-MPH Candidate.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

International Multi-Site and Multi-disciplinary Studies Thomas J. Coates PhD Director, UCLA Center for World Health Michael and Sue Steinberg Professor.

Patterns of sex and PrEP in Bangkok MSM (HPTN 067/ADAPT Study) Tareerat Chemnasiri, Anchalee Varangrat, K. Rivet Amico, Supaporn Chaikummao, Anupong Chitwarakorn,

The safety of HIV pre-exposure prophylaxis in the presence of hepatitis B infection Marc M. Solomon, Mauro Schechter, Albert Y. Liu, Vanessa McMahan, Juan.

Effect of Early versus Delayed Initiation of Antiretroviral Therapy (ART) on Clinical Outcomes in the HPTN 052 Randomized Clinical Trial Beatriz Grinsztejn.

HIV Prevention Trials Network Update Africa Regional Working Group 20 May 2003.

Community Representation Structure. Site Coordinating Centers (SCC) Community Advisory Boards (CABs) Leadership Level Cross-Network Level Network Level.

Family Health International Kenneth F. Schulz, PhD, MBA Science for Global Action and Impact.

Beatriz Grinsztejn, MD Site Investigator Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz 6 th IAS Conference, Rome, Italy July 18, 2011 Effects of.

THE BODY PRO The HIV Resource for Health Care Professionals Copyright © 2009 The HealthCentral Network, Inc. All rights reserved. This activity is jointly.

Individualizing Care in HIV: A Critical Review of Treatment Options Presented by The Johns Hopkins University School of Medicine Produced in collaboration.

Sustained Treatment as Prevention: Unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN K.H.

Program Overview Supported by PEPFAR/HRSA & Office of AIDS Research/NIH.

HIVNET 023 Sponsored by the US National Institute of Allergy and Infectious Diseases, National Institute of Health through the HIV Prevention Trials Network.

Botswana Experience on Public- Private Partnerships Joconiah Chirenda, MD, MPH, MBA Global Business Coalition on.

Page 1 Increasing rates of earlier antiretroviral treatment associated with elevated levels of optimal virologic response among HIV-positive illicit drug.

HPTN Future Directions January 22, 2003 Bethesda, MD.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Fred Gordin Chief, Infectious Diseases Veterans Affairs Medical Center; Washington DC Professor of Medicine; The George Washington University

XIX International AIDS Conference 25 July 2012 Lee Hall, MD, PhD Chief, Parasitology & International Programs Branch Division of Microbiology & Infectious.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

Washington D.C., USA, July 2012www.aids2012.org Pregnancy and HIV Acquisition Nelly Mugo Kenyatta National Hospital/ University of Washington Hormonal.

A Qualitative Analysis of HIV Testing Behaviors among Black MSM in Atlanta, Georgia, USA SOPHIA HUSSEN MD, MPH, ROBERT STEPHENSON PHD, CARLOS DEL RIO,

Implications of Anal Intercourse and Rectal use of Products in Vaginal Microbicide Trials Ian McGowan MD PhD FRCP.

Community-Level HIV Incidence Outcomes of NIMH Project Accept (HPTN 043) Glenda Gray for the Project Accept Study Team IAS July 2013 Kuala Lumpur,

HANC and Community Partners Overview November 20, 2007 Michael Petillo, Project Coordinator.

The DART Trial Evaluates two strategies for delivering ART, comparing: clinical monitoring only with routine laboratory + clinical monitoring structured.

Correlates of HIV incidence among black men who have sex with men in 6 U.S. cities (HPTN 061) B. KOBLIN, K. MAYER, S. ESHLEMAN, L. WANG, S. SHOPTAW, C.

Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.

Clinical Trials and IMPAACT: Clinical Trials and IMPAACT: Technological Challenges and Strategic Opportunities Technological Challenges and Strategic Opportunities.

Washington D.C., USA, July 2012www.aids2012.org Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples: a systematic.

Phase III Microbicide Trials Update Dr. Lut Van Damme IAS Conference Sydney, Australia July 2007.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER HIV Prevention in Clinical Care Settings Jeanne Marrazzo, MD, MPH Professor, Division of Allergy and Infectious.

© 2006 Baylor College of Medicine Antiretroviral Treatment for Children in Resource-Limited Settings: Africa Mark W. Kline, M.D.

UNC-SOM in Malawi Summer Research and the Carolina Covenant/ Medical Horizons Fellowship.

HPTN 073: Successful Engagement of Black MSM into a Culturally Relevant Clinical Trial for PrEP Christopher Hucks-Ortiz, MPH on behalf of the HPTN Protocol.

Funding Opportunities at the NIH-funded Centers for AIDS Research

HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.

Prevention Solutions for the Next Generation: Highlighting Adolescent Research in the NIH HIV/AIDS Clinical Trials Networks and the Adolescent Trials Network.

Integrating Evaluation with Business Process Modeling for Increased Efficiency and Faster Results in HIV/AIDS Clinical Trials Research Jonathan M Kagan.

NIMH Project Accept (HPTN 043) HIV/AIDS Community mobilization (CM) and Mobile HIV voluntary counseling and testing (MVCT) utilization in rural Thai.

Richard hayes London school of hygiene & Tropical Medicine

Community Advocacy & Education to End Stigmatizing HIV/TB Language

Introduction Sample text for bullet And another bullet goes here

Katharina Hauck On behalf of the HPTN 071 Study Team

INTERNATIONAL AIDS SOCIETY Stakeholder consultation to address issues related to tenofovir prophylactic research SUMMARY MEETING UPDATE, MAY 2005, SEATTLE,

Introduction Sample text for bullet And another bullet goes here

Jim K. Aizire, MD, MHS, PhD Johns Hopkins University

Introduction Sample text for bullet And another bullet goes here

PrEParedness for the Rollout of Effective HIV Prevention among Key Affected Populations in Brazil, Peru, and Mexico The Imprep pROJECT Valdiléa G. Veloso,

Introduction Sample text for bullet And another bullet goes here

Adolescent and young people’s participation and representation in clinical trials: lessons from a community-wide HIV testing and treatment study, the HPTN.

The Fenway Institute, Fenway Health, Boston, MA

Introduction Sample text for bullet And another bullet goes here

National Institutes of Health

Prevention Solutions for the Next Generation: Highlighting Adolescent Research in the NIH HIV/AIDS Clinical Trials Networks and the Adolescent Trials Network.

HPTN International Scholar ( )

Conducting NIH-Sponsored Social and Behavioral Science for the Past 15 Years: Reflections from South Africa Heidi van Rooyen Executive Director: HSRC Professor:

Presentation transcript:

Myron S. Cohen, MD Protocol Chair 6 th IAS Conference, Rome, Italy July 18, 2011 HPTN 052: Summary

Early ART prevented linked transmission of HIV Unlinked transmissions were noted despite intensive couples counseling Early ART reduced the number of clinical events observed Regional differences in HIV transmission associated with ART were noted HPTN 052: Session Highlights

The HIV prevention effect demonstrated in HPTN 052 is the proof of a concept These results could inform –The “Test and Treat” strategies –Management of HIV discordant couples HPTN 052: Implications

HPTN 052 Recognition U.S. Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) / U.S. National Institutes of Health (NIH) HIV Prevention Trials Network (HPTN): Network Laboratory, Johns Hopkins University Statistical Center for HIV/AIDS Research & Prevention (SCHARP) and University of Washington Coordinating and Operations Center, Family Health International (FHI) HPTN Leadership AIDS Clinical Trials Group (ACTG): ACTG Leadership and Investigators Pharmaceutical Companies: Abbott Laboratories Boehringer Ingelheim Pharmaceuticals, Inc. Bristol-Myers Squibb Gilead Sciences, Inc. GlaxoSmithKline/ViiV Healthcare Merck & Co., Inc. Sites (Investigators of Record): Porto Alegre, Brazil (Breno Santos) Rio de Janeiro, Brazil (Beatriz Grinsztejn) Boston, United States (Kenneth Mayer) Chennai, India (N. Kumarasamy) Pune, India (Sheela Godbole) Chiang Mai, Thailand (Suwat Chariyalertsak) Gaborone, Botswana (Joseph Makhema) Kisumu, Kenya (Lisa Mills) Blantyre, Malawi (Johnstone Kumwenda) Lilongwe, Malawi (Mina Hosseinipour) Johannesburg, South Africa (Ian Sanne) Soweto, South Africa (Guy De Bruyn) Harare, Zimbabwe (James Hakim) Study Participants!